Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Cheung, Rose; Morrell, Jonathan; Kallend, David; Watkins, Claire; Schuster, Herbert

doi:10.1016/j.ijcard.2004.12.011

Cited by 22 publications

(9 citation statements)

References 23 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was of interest that in this very large database, the percentage increases in apoA-I were comparable to those of HDL-C with all doses of the three statins. This contrasted with many previous reports that HDL-C-raising therapies tend to increase the concentration of HDL-C to a greater extent than that of apoA-I ( 3,5,6,(11)(12)(13)(14)(15)(16).…”

Section: Relationship Between Changes In Hdl-c and Changes In Apoa-icontrasting

confidence: 99%

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Barter

Brandrup‐Wognsen

Palmér

et al. 2010

Journal of Lipid Research

215

159

View full text Add to dashboard Cite

Section: Relationship Between Changes In Hdl-c and Changes In Apoa-icontrasting

confidence: 99%

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Barter

Brandrup‐Wognsen

Palmér

et al. 2010

Journal of Lipid Research

215

159

View full text Add to dashboard Cite

“…The relation between atherogenic and antiatherogenic lipids or lipoproteins, also known as atherogenic indices, are useful clinical risk indicators for the development of coronary diseases and other clinical manifestations of atherosclerosis. Numerous studies have shown good prognostic characteristics of the LDL-C/HDL-C and TC/HDL-C indices used to determine the onset of a CD (7,8). However, this study did not show a significant reduction of these markers in the target groups, which points to the insufficient antilipemic potential of the applied statin therapy (Table II).…”

Section: Discussioncontrasting

confidence: 58%

Lipid Disorders And Inflammation in Patients With Diabetes Mellitus Type 2 Treated With Statins

Jovović¹,

Lecic²,

Jelić³

et al. 2007

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Lipid Disorders And Inflammation in Patients With Diabetes Mellitus Type 2 Treated With Statins The research focused on 40 patients (22 women and 18 men) with DM type 2, 26 of who underwent statin therapy and 14 of them followed a hygienic-dietetic regime. After a year of careful observation, the concentration of triglycerides (TG) was determined, as well as the overall cholesterol (TC), LDL-C, HDL-C, nonHDL cholesterol and atherogenic indices. As far as inflammatory indicators are concerned, the concentrations of highly sensitive C reactive protein (hsCRP), intracellular adhesion molecule (ICAM-1) and vascular adhesion molecule (VCAM-1) were determined; they were also compared among the therapy groups. The average TC and LDL-C values were considerably lower in the group treated by statins (5.6 ± 1.2 vs. 6.3 ± 1.4 mmol/L and 3.5 ± 0.9 vs. 4 ± 1.3 mmol/L, p<0.05). The values of TG, HDL-C, atherogenic indices LDL-C/HDL-C and TC/HDL-C and inflammatory indicators ICAM-1 and VCAM-1 did not differ significantly among the groups. The values of nonHDL-C were considerably lower in the group treated by statins (4.5 ± 1.1 vs. 5.1 ± 1.3 mmol/L, p<0.05), as well as the values of hsCRP (3.3 ± 2.2 vs. 5.6 ± 2.17 mg/dl, p<0.01). Parallel analysis showed a significant correlation between the concentration of TC and LDL-C and the values of ICAM-1 (C=0.55 and C=0.65, p<0.05). Anti-lipoid effects of statins are complemented with their significant antiinflammatory influence on the reduction of the value of hsCRP, which proved to be the most important prognostic factor for the onset of atherosclerosis. Antiinflammatory effects of statins are supplemented by a significant decrease in the concentration of ICAM-1 in the conditions where the value of TC and LDL-C is reduced in patients with DM type 2.

show abstract

“…HDL particles draw out free cholesterol from the peripheral tissues in the reverse cholesterol transport system, and the HDL-C value is known to have a negative correlation with ischemic heart disease [19]. In a recent study [20] comparing the usefulness of atorvastatin and rosuvastatin, the latter was significantly more effective in elevating HDL-C and Apo A-I levels, a tendency also observed in a subgroup taking ezetimibe as an add-on therapy in our present study Table 2. In the present study, particularly in patients with a baseline HDL-C level of 35mg/dl or below, the change in HDL-C varied greatly among the different statins when ezetimibe was added, suggesting varied influence in the metabolism of statins affected by ezetimibe.…”

Section: Discussionmentioning

confidence: 99%

Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?

Inoue¹,

Awata²,

Katayama³

2010

PRC

View full text Add to dashboard Cite

Lipid profiles were evaluated for 281 dyslipidemia patients treated with HMG-CoA reductase inhibitors (statins) for 2 years. The efficacy and safety of ezetimibe 10 mg/day one-year add-on therapy were also retrospectively evaluated. The results show that in 281 dyslipidemia patients with a mean low-density lipoprotein-cholesterol (LDL-C) level of 120 mg/dl or greater, ezetimibe 10 mg/day administration reduced LDL-C levels to 90 mg/dl or below. Patients who had been treated with one of six statins (pravastatin, simvastatin, fluvastatin, pitavastatin, atorvastatin, and rosuvastatin) for one year were given ezetimibe add-on therapy for one year, which reduced their LDL-C levels by 18% (pravastatin), 25% (simvastatin), 27% (fluvastatin), 30% (pitavastatin), 29% (atorvastatin), and 31% (rosuvastatin). Also, during the one-year add-on therapy, no severe adverse event was detected. An analysis of associations among lipids during a two-year lipid-lowering pharmacotherapy revealed correlations in a single patient. The correlation was between LDL-C and small, dense LDL as well as mid-band lipoprotein cholesterol. In conclusion, ezetimibe 10mg/day add-on therapy may be safe and effective for treating dislipidemia patients who have been treated with a statin. Moreover, this article discusses the disappearance thresholds for small, dense LDL and intermediate-density lipoprotein (IDL) by using the quantitative analysis of densitometric pattern based on genetic algorithm, which indicated that the major eight subspecies of lipoprotein (VLDL1, VLDL2, IDL1, IDL2, LDL1, LDL2, LDL3, HDL). The thershold for small dense LDL indicates the IDL1 plus IDL2 when LDL2 and LDL3 were not detectable, while the thershold for IDL indicates the LDL1 when IDL1, IDL2 and LDL3 were not detectable.

show abstract

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Cited by 22 publications

References 23 publications

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

Lipid Disorders And Inflammation in Patients With Diabetes Mellitus Type 2 Treated With Statins

Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?

Contact Info

Product

Resources

About